Multibagger Selection: Claude Opus 5.5's picks
Claude Opus 5.5 picked INBX, CRML, LUNR, RDW, SRZN with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INBX | — | 55% | — | — |
| 2 | CRML | — | 40% | — | — |
| 3 | LUNR | — | 58% | — | — |
| 4 | RDW | — | 55% | — | — |
| 5 | SRZN | — | 38% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -5.06% | -5.58% | 1.07x | 0 |
| 1 month | -22.21% | -21.24% | 1.07x | 0 |
The model's market view
Conditions for small and mid-cap multibagger candidates are mixed but supportive for catalyst-rich names. Oil is easing from above $100, Treasury yields are coming off multi-decade highs, and risk appetite remains concentrated in AI, space/defense and geopolitically linked themes such as the US-Denmark-Greenland security pact. At the same time, a volatility gauge is on track for its largest weekly jump in over a year, and speculative small caps have shown violent reversals, so dilution and valuation-compression risk are elevated. The strongest set-ups combine a dated, verifiable binary or operational catalyst with either a demonstrated revenue and margin inflection (LUNR, RDW) or a regulatory event on an asset the market may be under-pricing (INBX). Theme-driven developers (CRML) and preclinical-to-clinical biotech (SRZN) offer high convexity but weak fundamentals. Research was time-constrained: several figures are from third-party data providers rather than primary filings and are labelled as such. Where I could not verify a figure it is marked 'data unconfirmed'. None of these is presented as a likely 3x.
Why each pick
INBX
Inhibrx has a registrational-stage asset with an FDA decision inside the 12-month window. The FDA accepted the BLA for ozekibart (INBRX-109) in unresectable or metastatic conventional chondrosarcoma with no filing review issues and a PDUFA goal date of April 14, 2027. The supporting ChonDRAgon registrational trial met its primary PFS endpoint, with a 52% reduction in risk of progression versus placebo. If approved, it would be the first approved therapy for this indication. Additional value drivers: interim data from two new colorectal cancer cohorts are expected in Q1 2027; the company plans Q4 2026 FDA meetings on a first-line CRC registrational trial and a possible accelerated path in fourth-line CRC; and INBRX-106 posted positive Phase 2 data with Keytruda in first-line head and neck cancer, with a Reuters report that Merck and rivals were eyeing a deal (a deal is unconfirmed and not assumed here). Analyst price targets per Yahoo Finance range from $230 to $325 (average $266.67) against a $112.04 price. The market cap sits well inside the $200M-$5B band, and average dollar volume is about $35M/day (316K shares × ~$112). Price note: 112.04 is the regular-session close from September 21, 2026 on Yahoo Finance, four sessions stale; I could not retrieve a fresher quote.
CRML
Critical Metals is a pre-revenue developer of the Tanbreez heavy rare earth project in southern Greenland (92.5% ownership approved by Greenland's government on April 17, 2026) and the Wolfsberg lithium project in Austria. The investment case rests on project de-risking during a period of strong Western policy support for non-Chinese rare earth supply. Tangible steps so far: a binding 15-year offtake with REalloys for 15% of Phase 1 concentrate (May 21, 2026), assay results from 33 drill holes, a 150-tonne bulk sample program, and a refinery study for a proposed Romanian joint venture. The September 21, 2026 US-Denmark-Greenland security pact lowered the perceived political risk premium. The stock is highly liquid (10-day average volume about 13.8M shares per CNBC, far above $5M/day) but has a history of extreme swings: its 52-week range is $5.12 to $32.15, and at the $32.15 high it traded at more than 4x the current price. Price note: 7.72 is the regular-session close on September 24, 2026 from Investing.com; I could not verify a September 25 intraday quote.
LUNR
Intuitive Machines shows the clearest verified operating inflection in this set. Q2 2026 revenue was $206.2M, more than 4x Q2 2025. TTM revenue is $490.1M (+116.9%), against FY2025 revenue of $210.1M. Management reaffirmed FY2026 revenue of $900M-$1B (consensus about $950.7M) with positive adjusted EBITDA, and quarter-end backlog reached a record $1.8B with $1.7B of year-to-date bookings. Recent contract flow is broad: a multi-satellite communications program worth more than $600M (authorization to proceed from an undisclosed customer), a NASA JPL EAGLE-VSWIR spacecraft award, an order for two IM 300 platforms from a new customer, and in-orbit delivery of the SXM-11 satellite to SiriusXM. The stock is about 66% below its 52-week high of $46.75, with nine analysts at Strong Buy and a $29.50 average target (StockAnalysis), although BofA remains at Underperform with a $13 target. Liquidity is ample (about 8.07M shares × $15.70 ≈ $127M on September 24). Price note: 15.89 is a pre-market quote from 9:02 AM ET on September 25, 2026 (StockAnalysis); the September 24 close was 15.70.
RDW
Redwire shows a documented revenue acceleration and gross-margin inflection sequence. Q2 2026 revenue was a record $117.1M, up 90% YoY and ahead of the $107.7M consensus. Gross margin reached a record 28%, versus -31% in Q2 2025. Net loss narrowed by $56.0M to -$41.0M. Backlog rose to $542.1M from $411.2M at year-end 2025, with book-to-bill of 1.42. FY2026 revenue guidance of $450-500M was reaffirmed, versus FY2025 revenue of $335.4M. On September 24, 2026 the company was selected as one of 15 vendors on Space Systems Command's $980M NITE-STAR IDIQ. Analyst coverage is broadening (Guggenheim initiated at Neutral about 10 days ago; 10 analysts, $14.69 average target), though BofA has an $8 Underperform target. The stock is down from a 52-week high of $26.64. Price note: 11.97 is a live quote from 9:41 AM ET on September 25, 2026 (StockAnalysis).
SRZN
Surrozen is a Wnt-pathway ophthalmology biotech whose lead candidate SZN-8141 (a bifunctional Wnt agonist plus VEGF antagonist for diabetic macular edema) had its IND submitted on September 8, 2026. The company guided to starting the DUET Phase 1b/2a study by year-end 2026, with initial data expected in 2027. On September 24 the stock more than doubled (+108.4% to $33.68). H.C. Wainwright attributed the move to Merck's remigromig data, which appears to validate the Wnt-agonist approach in retinal disease, and raised its target to $54 from $44. Six analysts rate the stock Strong Buy with a $44.80 average target (StockAnalysis). At about $393M market cap it offers the highest percentage convexity in this set, but its own asset has no human efficacy data yet, which is why it ranks last. Liquidity: 11.5M shares traded on September 24 (about $390M); normal-day average dollar volume is data unconfirmed and may be near the $5M threshold. Price note: 33.40 is a live quote from 10:28 AM ET on September 25, 2026 (StockAnalysis).
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 1.5 Pro | DLO, TBN, IRON, AGYS, VNDA |
| Muse Spark 1.1 | ENVA, SMR, RARE, CAPR, INDP |
| Perplexity | LQDA, AAOI, CRDO, RDW, POET |
| Grok 4.5 | AESI, SOUN, PRME, MYRG, VSEC |
| GPT-5.6 Sol | CAPR, NTLA, BEAM, LUNR, RXRX |
| DeepSeek | QMLS, DUOT, TLSI, NUAI, OPTX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.